GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Hester Biosciences Ltd

Hester Biosciences: Board recommends Ms. Priya Gandhi's re-appointment as ED

MANAGEMENT ● No Immediate Change LOW RISK
📅 Filed on BSE: 15 May 2026, 12:08 PM IST  ·  BSE ID: 21cccac0-da23-4bd2-90e7-14f70313ce0b
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board proposed keeping Ms. Priya Gandhi as an Executive Director and announced financial results and a dividend.
🤖 AI Summary
  • Hester Biosciences Board recommended re-appointment of Ms. Priya Gandhi as Executive Director for three years.
  • The re-appointment is effective from 28 October 2026, subject to approval from members.
  • Board approved Audited Standalone and Consolidated Financial Results for quarter and year ended 31 March 2026.
  • Board recommended dividend of INR 11 per equity share (110%) for financial year 2025-26.
  • Statutory Auditors issued an unmodified opinion on the Audited Standalone and Consolidated Financial Results.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Recommended Dividend per Share
INR 11
Dividend Percentage on Face Value
110%
Executive Director Re-appointment Term
3 years
🏢 How This Affects the Company
⚙️
Operational Impact
The re-appointment of an Executive Director ensures continuity in the company's senior management team and operational leadership from October 28, 2026.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will need to vote on the re-appointment of Ms. Priya Gandhi and the recommended dividend at the upcoming Annual General Meeting.
👤
Who Is Affected
All equity shareholders will be affected by the dividend recommendation of INR 11 per equity share for FY2025-26, pending AGM approval, which impacts their potential returns.
🔍
Management Signal
The Board's recommendation for Ms. Priya Gandhi's re-appointment signals an intent to maintain continuity in executive leadership and strategic direction.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Annual General Meeting date — for shareholder approvals on re-appointment and dividend.
Dividend record date — to ascertain eligibility for the recommended INR 11 dividend.
Completion of re-appointment — confirmation of Ms. Priya Gandhi's new term effective October 28, 2026.
LOW RISK The filing primarily details routine corporate governance decisions and financial result approval.
💡 Investor Takeaway
Hester Biosciences' Board recommended re-appointing Ms. Priya Gandhi as Executive Director for three years, starting October 28, 2026, subject to shareholder approval. The Board also approved FY2025-26 audited financial results and a recommended dividend of INR 11 per equity share.
⚖️ Strengths & Concerns

✅ Positives

  • Board recommended a dividend of INR 11 per equity share for FY2025-26, indicating shareholder returns subject to approval.
  • Statutory Auditors provided an unmodified opinion on the audited financial results for FY2025-26, confirming financial reporting quality.
📅 Company Track Record
Ms. Priya Gandhi has been associated with Hester Biosciences since 2016, currently serving as Executive Director. Previously, on May 12, 2026, Non-Executive Director Ravin Gandhi resigned from the company.

Based on publicly available historical data. For context only.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.